St. john’s wort: nih study failed
St. John’s Wort: NIH study failed
On 10th April, 2002, the American medical journal JAMA (287: 1840 – 47)
published a controlled clinical study with St. John’s Wort extract. In the
following, the members of the “St. John’s Wort” International Consensus
Conference comment on the published data.
The authors treated 340 patients with moderately severe depression for eight weekswith placebo, 900 to 1500 mg St. John’s Wort (LI160) or 50 to 100 mg sertraline(Zoloftâ). The aim of this study was to confirm the efficacy of the therapy by means
of changes in the Hamilton scale (HAMD) and – as secondary parameter – with thehelp of the clinical global impression (CGI). At the end of the study, neither thechanges in HAMD nor in the CGI showed a significant difference between patientstreated with placebo, sertraline or St. John’s Wort.
How can these results be interpreted?
To begin with, it should be stated that the improvement in the placebo patients of 31percent corresponds with the general results of other studies. In an analysis of 75studies this was 29.7 percent (Journal for Phytotherapy 2002; 23: 11-15). Undersertraline – a wel -documented so-called SSRI – the condition had improved in only24.8 percent of patients, under St. John’s Wort (LI160) an improvement occurred in23.9 percent. Since no differences were obtained between the three very differenttreatment alternatives in this study, only one conclusion may be drawn: It is notsuitable for evaluating the efficacy of either sertraline or St. John’s Wort.
With the clinical picture of depression, it is not unusual that studies are withouttangible results. Due to the important role that caring plays for these patients, it isoften the case that additional effects of the medication cannot be statisticallydemonstrated. For this reason, careful y performed meta-analyses are particularlyimportant, especially in the evaluation of the efficacy of a therapy for depression, asthe individual results are thereby placed in a larger context.
The study is a failure, it could document the efficacy of neither the standardantidepressant sertraline nor St. John’s Wort. It is unfortunate that a study which cost4 million dollars produced such disappointing results. However, these high researchcosts should not induce one to attach an importance to the data which is not justifiedby objective standards. This study does not call the proven efficacy of sertraline norof St. John’s Wort extracts into question.
Prof. Siegfried KasperDepartment of General Psychiatry,University of Vienna, Vienna, Austria
Prof. Walter E. MüllerDepartment of Pharmacology, Biocenter Niederursel,University of Frankfurt, Frankfurt/Main, Germany
Prof. Ivar RootsInstitut for clinical Pharmacology and ToxicologyUniversity Hostpital CharitéBerlin, Germany
Prof. Hilke WinterhoffInstitute of PharmacologyUniversity of Münster, Germany
Source: Komitee Forschung Naturmedizin KFN 7/2002
The complete text of the English publication in the journal JAMA can be found under:
Join the link below for further information on this study
A primer on generics A PATENT gives an innovator a monopoly over an innovation for a fixed period. This is meant to encourage innovation by allowing the innovator to extract the highest possible benefit during the In the US, pharmaceutical products receive a 20-year patent. During the patent's life, the innovator has complete monopoly over the commercial aspect of the patent. For instance,
MIRALAX/ GATORADE PREPARATION Please read these directions thoroughly one week before your procedure. Please arrange to have someone accompany you to drive you home. To prevent to risk of bleeding, aspirin products and blood thinners such as Coumadin, Plavix, and Pradaxa, should be held. REMEMBER: The preparation is very important. An adequate clean out allows for the best evaluation